Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elagolix. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 20/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.95 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.87 |
| ▸ | APLNR | P35414 | 1/20 | 0.87 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.87 |
| ▸ | GLP1R | P43220 | 1/20 | 0.87 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.87 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.87 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elagolix SCHEMBL4677617 | 0.99 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL29396002 | 0.99 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL19549512 | 0.99 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL29365599 | 0.99 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL1642523 | 0.99 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL1641993 | 0.99 | GNRHR (0.99) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL4995673 | 0.95 | GNRHR (0.92) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL17946057 | 0.94 | GNRHR (0.91) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL23958974 | 0.94 | GNRHR (0.90) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL20741205 | 0.93 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218191-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2019-07-18 | — | — | US | claimed |
| US-11980621-B2 | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2024-05-14 | — | — | US | disclosed |
| WO-2021083554-A1 | 3-((R)-2-(AMINO-2-PHENYLETHYL)-1-(2-FLUORO-6-TRIFLUOROMETHYL BENZYL)-5-IODO-6-METHYL-1H-PYRIMIDINE-2,4-DIONE OR A SALT THEREOF, PROCESS FOR ITS PREPARATION, AND ITS USE IN THE SYNTHESIS OF ELAGOLIX | MOEHS IBERICA, S.L. (ES) | 2021-05-06 | — | — | WO | disclosed |
| CN-112533603-A | Administration regimen for oxadegril | 艾伯维公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20200268752-A1 | METHODS OF ADMINISTERING ELAGOLIX | ABBVIE INC. | 2020-08-27 | — | — | US | disclosed |
| US-20200255387-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10682351-B2 | Methods of administering elagolix | ABBVIE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| CN-111246850-A | Solid pharmaceutical formulation for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis | 艾伯维公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20200138819-A1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200121680-A1 | METHODS OF ADMINISTERING ELAGOLIX | ABBVIE INC. | 2020-04-23 | — | — | US | disclosed |
| US-20180346428-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20180235963-A1 | METHODS OF ADMINISTERING ELAGOLIX | ABBVIE INC. | 2018-08-23 | — | — | US | disclosed |
| US-9949974-B2 | Methods of adminstering elagolix | ABBVIE INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9868706-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170320836-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170056403-A1 | METHODS OF ADMINISTERING ELAGOLIX | ABBVIE INC. | 2017-03-02 | — | — | US | disclosed |
| US-9382214-B2 | Processes for the preparation of uracil derivatives | Neurocine Biosciences, Inc. (US) | 2016-07-05 | — | — | US | disclosed |
| US-8765948-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110098472-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2011-04-28 | — | — | US | disclosed |
| WO-2009062087-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980621-B2 | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis | GNRHR, FSHR, LHCGR | GNRHR 1/4885CYP3A4 2733/4885ADRB2 612/4885 |
| US-20200255387-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885ADRB2 1892/4885 |
| US-20200138819-A1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | GNRHR, FSHR, LHCGR | GNRHR 1/4885CYP3A4 2733/4885ADRB2 612/4885 |
| US-20190218191-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885ADRB2 1892/4885 |
| US-20180346428-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885ADRB2 1892/4885 |
| US-20110098472-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885ADRB2 1892/4885 |
| US-20170320836-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885ADRB2 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.